• Mon news: Autolus enters CAR-T race with FDA approval. FDA clears clinical hold on Novavax. AbbVie schizophrenia trial failure. Cigna not pursuing Humana. GSK leaving BIO. See more on our front page

Allergan lifts 2017 guidance, but Teva sell-off pulls it down





or, investors have finally determined that Allergan's numbers are complete shit. Full year guidance of GAAP losses of $12 a share, but "non-GAAP" earnings of $16 a share ... Only at Valeant would you see manipulation like that! Even beating revenue numbers didn't get any movement.
 




The 6 months ending June of 2016 Allergan had an operating loss of $659 million. for the 6 months ending June for 2017, that operating loss was $1.8 billion.

That's 174% more in operating losses. I'm pretty sure that we have operated at a loss every quarter for two years. It proves that you can be horrible at your job and be in a position of power. Atta boy Brent...you are killing it!